Colorectal cancer and canonical Wnt signalling pathway

1. International variations and trends AND Colon and rectum. In: World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition and physical activity, and the prevention of cancer: a global perpective. Washington DC: AICR 2007; 20, 280–288.

2. Dušek L, et al. Populační odhady počtu nemocných s kolorektálním karcinomem v ČR – jeden z nástrojů hodnocení včasné diagnostiky časných stadií a rekurence onemocnění. Farmakoterapie 2009; 5: 11–20.

3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.

4. Najdi R, et al. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog 2011; 10: 5.

5. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781–810.

6. MacDonald BT, et al. Wnt/ß-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9–26.

7. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136: 3205–3214.

8. Verheyen EM, Gottardi CJ. Regulation of Wnt/ß-catenin signaling by protein kinases. Dev Dyn 2010; 239: 34–44.

9. Doucas H, et al. Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 2005; 41: 365–379.

10. Nusse R. Cancer. Converging on beta-catenin in Wilms tumor. Science 2007; 316: 988–989.

11. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45–51.

12. Gallagher JC, Sai AJ. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas 2010; 65: 301–307.

13. Vlad A, et al. The first five years of the Wnt targetome. Cell Signal 2008; 20: 795–802.

14. van Amerongen R, et al. Alternative Wnt signaling is initiated by distinct receptors. Sci Signal 2008; 1: re9.

15. Kikuchi A, et al. Multiplicity of interactions of Wnt proteins and their receptors. Cell Signal 2007; 19: 659–671.

16. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468–477.

17. Gao C, Chen YG. Dishevelled: The hub of Wnt signaling. Cell Signal 2010; 22: 717–727.

18. Caldwell GM, et al. Reorganisation of Wnt-response pathways in colorectal tumorigenesis. Br J Cancer 2008; 98: 1437–1442.

19. Toualbi K, et al. Physical and functional cooperation between AP-1 and ß-catenin for the regulation of TCF-dependent genes. Oncogene 2007; 26: 3492–3502.

20. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors and multiple transcription factors. J Biol Chem 2006; 281: 22429–22433.

21. Kohn AD, Moon RT. Wnt and calcium signaling: ß-catenin-independent pathways. Cell Calcium 2005; 38: 439–446.

22. Veeman MT, et al. A second canon: functions and mechanisms of ß-catenin-independent Wnt signaling. Dev Cell 2003; 5: 367–377.

23. Seifert JR, Mlodzik M. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 2007; 8: 126–138.

24. Semenov MV, et al. SnapShot: noncanonical Wnt signaling pathways. Cell 2007; 131: 1378.

25. van den Brink GR, Offerhaus GJ. The morphogenetic code and colon cancer development. Cancer Cell 2007; 11: 109–117.

26. Steinhauer J, Treisman JE. Lipid-modified morphogens: functions of fats. Curr Opin Genet Dev 2009; 19: 308–314.

27. van den Heuvel M, et al. Mutations in the segment polarity genes wingless and porcupine impair secretion of the wingless protein. EMBO J 1993; 12: 5293–5302.

28. Leronowicz MJ, Korswagen HC. Sailing with the Wnt: charting the Wnt processing and secretion route. Exp Cell Res 2009; 315: 2683–2689.

29. Port F, Basler K. Wnt trafficking: new insights into Wnt maturation, secretion and spreading. Traffic 2010; 11: 1265–1271.

30. Mikels AJ, Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006; 25: 7461–7468.

31. Takei Y, et al. Three Drosophila EXT genes shape morphogen gradients through synthesis of heparan sulfate proteoglycans. Development 2004; 131: 73–82.

32. Korkut C, et al. Trans-synaptic transmission of vesicular Wnt signals through Evi/Wntless. Cell 209; 139: 393–404.

33. Panáková D, et al. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 2005; 435: 58–65.

34. Neumann S, et al. Mammalian Wnt3a is released on lipoprotein particles. Traffic 2009; 10: 334–343.

35. Bovolenta P, et al. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 2008; 121: 737–746.

36. Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci 2006; 119: 395–402.

37. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483–1487.

38. Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007; 56: 417–425.

39. Lee E, et al. The role of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003; 1: E10.

40. Chia IV, Constantini F. Mouse axin and axin2/conductin proteins are functionally equivalent in vivo. Mol Cell Biol 2005; 25: 4371–4376.

41. Lustig B, et al. Negative feedback loop of Wnt signaling through upregulation of Conductin/Axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22: 1184–1193.

42. Mosimann C, et al. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009; 10: 276–286.

43. Arce L, et al. Diversity of LEF/TCF action in development and disease. Oncogene 2006; 25: 7492–7504.

44. Roose J, et al. Synergy between tumor suppressor APC and the beta-catenin-TCF4 target TCF1. Science 1999; 285: 1923–1926.

45. Aguilera O, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006; 25: 4116–4121.

46. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422–426.

47. Arber N, et al. Increased expression of Cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996; 110: 669–674.

48. Zhang T, et al. Evidence that APC regulates survivin expression: possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001; 61: 8664–8667.

49. Brabletz T, et al. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155(1999): 1033–1038.

50. Kim TH, et al. Beta-catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 2005; 24: 597–604.

51. Batlle E, et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111: 251–263.

52. van de Wetering M, et al. The ß-catenin/TFC4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241–250.

53. Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468–476.

54. de Sousa EM, et al. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 2011; 17: 647–653.

55. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2001; 18 Suppl 2: 1–5.

56. Eaden JA, et al. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526–535.

57. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159–170.

58. Heinen CD, et al. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol Ther 2002; 1: 477–485.

59. Komarova NL, et al. Dynamics of genetic instability in sporadic and familial colorectal cancer. Cancer Biol Ther 2002; 1: 685–692.

60. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohnęs disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35: 950–954.

61. O’Sullivan JN, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002; 32: 280–284.

62. Harpaz N, Polydorides AD. Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 2010; 134: 876–895.

63. Watson AJ, Collins PD. Colon cancer: a civilization disorder. Dig Dis 2011; 29: 222–228.

64. Fodde R, et al. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1: 55–67.

65. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23: 11–27.

66. Thorstensen L, Lind GE, et al. Genetic and epigenetic changes of components affecting the Wnt pathway in colorectal carcinomas stratisfied by microsatellite instability. Neoplasia 2005; 7: 99–108.

67. Dhir M, et al. Epigenetic regulation of WNT signaling pathways genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg 2008; 12: 1745–1753.

68. Rudolph KL, et al. Telomere dysfunction and DNA damage checkpoints in diseases and cancer of the gastrointestinal tract. Gastroenterology 2009; 137: 754–762.

69. Watson AJ. Apoptosis and colorectal cancer. Gut 2004; 53: 1701–1709.

70. Oving IM, Clevers HC. Molecular causes of colon cancer. Eur J Clin Invest 2002; 32: 448–457.

71. Heinen CD, et al. Microsatellite instability in colorectal adenocarcinoma cell lines that have full-lenght adenomatous polyposis coli protein. Cancer Research 1995; 55: 4797–4799.

72. Sparks AB, et al. Mutational analysis of the APC/ß-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130–1134.

73. Miyaki M, et al. Frequent mutation of ß-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999; 59: 4506–4509.

74. Lammi L, et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004; 74: 1043–1050.

75. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311–320.

76. Suzuki H, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417–422.

77. Caldwell GM, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004; 64: 883–888.

78. Taniguchi H, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005; 24: 7946–7952.

79. Jen J, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54: 5523–5526.

80. Ijssennagger N, et al. Dietary haem stimulates epithelial cell turnover by downregulating feedback inhibitors of proliferation in murine colon. Gut 2011: (Epub ahead of print).

81. Duval A, et al. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 1999; 59: 4213–4215.

82. Shimizu Y, et al. Frequent alterations in the Wnt signaling pahtway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer 2002; 33: 73–81.

83. Waterman ML. Lymphoid enhancer factor/T cell factor expression in colorectal cancer. Cancer Metastasis Rev 2004; 23: 41–52.

84. Duval A, et al. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 2000; 60: 3872–3879.

85. Metcalfe C, Ibrahim AE, et al. Cancer Res 2010; 70: 6629–6638.

86. Korkaya H, Wicha MS. Cancer stem cells: nature versus nurture. Nat Cell Biol 2010; 12: 419–421.

87. Chan TL, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003; 63: 4878–4881.

88. Batlle E, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005; 435: 1126–1130.

89. Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 2006; 66: 2–5.

90. Yamamoto H, et al. Somatic frameshift mutation in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res 1998; 58: 997–1003.

91. Grady WM, et al. Mutation of the type II transforming growth factor–beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998; 58: 3101–3104.

92. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60: 116–129.

93. Ondřichová L. Metastazující kolorektální karcinom – nic není jako dřív. Medical Tribune 2011; 7(25): B2,B4.

94. Vyzula R, et al. Zhoubný novotvar kolorekta (C18–20). Zhoubný novotvar řiti a řitního kanálu (C21). In: Vyzula R, et al. Zásady cytostatické léčby maligních onkologických onemocnění. 14. vydání. Brno: KAPCZ 2012; 52–66.

95. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5: 997–1014.

96. Gehrke I, et al. Targeting the Wnt/beta-catenin/TCF/LEF1 axis in solid and haematologecal cancers: Multiplicity of therapeutic options. Eur J Cancer 2009; 45: 2759–2767.

97. He B, et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005; 24: 3054–3058.

98. Dihlmann S, et al. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005; 113: 515–524.

99. Lepourcelet M, et al. Small-molecule antagonists of the oncogenic TCF/beta-catenin protein complex. Cancer Cell 2004; 5: 91–102.

100. Shan J, et al. Identification of specific inhibitor of the Dishevelled PDZ domain. Biochemistry 2005; 44: 15495–15503.

101. Muller T, et al. Regulation of epithelial cell migration and tumor formation by beta–catenin signaling. Exp Cell Res 2002; 280: 119–133.

102. Wang MH, et al. Potential therapeutics specific to c-MET/RON receptor thyrosin kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010; 31: 1181–1188.

103. Bertagnolli MM, et al. Five year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2009; 2: 310–321.

104. Rothwell PM, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31–41.

105. Cook NR, et al. Low-dose aspirin in the primary prevention of cancer: the Womenęs Health Study: a randomized controlled trial. JAMA 2005; 294: 47–55.

106. Cuzick J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501–507.

107. Bordonaro M, et al. Butyrate-induced apoptotis cascade in colonic carcinoma cells: modulation of the ß-Catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Differ 1999; 10: 713–720.

108. Bordonaro M, et al. Cell type – and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate. Int J Cancer 2002; 97: 42–51.

109. Lazarova DL, et al. Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. Int J Cancer 2004; 110: 523–531.